A Case of Severe Diabetic Ketoacidosis Associated with Pembrolizumab Therapy in a Patient with Metastatic Melanoma

Lili Wu, Bixun Li Department of Integrated Medicine, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, 530021, People’s Republic of ChinaCorrespondence: Bixun LiDepartment of Integrated Medicine, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, 530021, People&r...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Wu L, Li B
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	dka diabetic ketoacidosis pembrolizumab metastatic melanoma Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/33fe7cab09894b2498cdbdf58308cf28
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:33fe7cab09894b2498cdbdf58308cf28
record_format	dspace
spelling	oai:doaj.org-article:33fe7cab09894b2498cdbdf58308cf282021-12-02T14:02:44ZA Case of Severe Diabetic Ketoacidosis Associated with Pembrolizumab Therapy in a Patient with Metastatic Melanoma1178-7007https://doaj.org/article/33fe7cab09894b2498cdbdf58308cf282021-02-01T00:00:00Zhttps://www.dovepress.com/a-case-of-severe-diabetic-ketoacidosis-associated-with-pembrolizumab-t-peer-reviewed-article-DMSOhttps://doaj.org/toc/1178-7007Lili Wu, Bixun Li Department of Integrated Medicine, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, 530021, People’s Republic of ChinaCorrespondence: Bixun LiDepartment of Integrated Medicine, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, 530021, People’s Republic of ChinaEmail 260228096@qq.comAbstract: Pembrolizumab, a monoclonal antibody against programmed cell death-1 receptor, was licensed for advanced cancers. Although the use of pembrolizumab can enhance the effect of cancer treatment, it can increase immune-related adverse events. We describe an elderly woman who developed ketoacidosis after receiving pembrolizumab to treat metastatic melanoma. In the presentation, laboratory analysis showed that hyperglycemia and anion gap metabolic acidosis was consistent with diabetic ketoacidosis. Except for pembrolizumab, no other predisposing factors were found. The blood glucose levels before using pembrolizumab were normal. The patient responded well to intravenous fluids, insulin therapy, and treatment to correct electrolyte disturbances. She was diagnosed with severe diabetic ketoacidosis (DKA) because of new-onset diabetes mellitus which associated with pembrolizumab therapy. Two months after she was discharged from the hospital, she continued to take insulin as well as metformin to treat her diabetes. Clinicians need to be alert about diabetes mellitus and ketoacidosis for patients undergoing pembrolizumab treatment.Keywords: DKA, diabetic ketoacidosis, pembrolizumab, metastatic melanomaWu LLi BDove Medical Pressarticledkadiabetic ketoacidosispembrolizumabmetastatic melanomaSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol Volume 14, Pp 753-757 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	dka diabetic ketoacidosis pembrolizumab metastatic melanoma Specialties of internal medicine RC581-951
spellingShingle	dka diabetic ketoacidosis pembrolizumab metastatic melanoma Specialties of internal medicine RC581-951 Wu L Li B A Case of Severe Diabetic Ketoacidosis Associated with Pembrolizumab Therapy in a Patient with Metastatic Melanoma
description	Lili Wu, Bixun Li Department of Integrated Medicine, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, 530021, People’s Republic of ChinaCorrespondence: Bixun LiDepartment of Integrated Medicine, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, 530021, People’s Republic of ChinaEmail 260228096@qq.comAbstract: Pembrolizumab, a monoclonal antibody against programmed cell death-1 receptor, was licensed for advanced cancers. Although the use of pembrolizumab can enhance the effect of cancer treatment, it can increase immune-related adverse events. We describe an elderly woman who developed ketoacidosis after receiving pembrolizumab to treat metastatic melanoma. In the presentation, laboratory analysis showed that hyperglycemia and anion gap metabolic acidosis was consistent with diabetic ketoacidosis. Except for pembrolizumab, no other predisposing factors were found. The blood glucose levels before using pembrolizumab were normal. The patient responded well to intravenous fluids, insulin therapy, and treatment to correct electrolyte disturbances. She was diagnosed with severe diabetic ketoacidosis (DKA) because of new-onset diabetes mellitus which associated with pembrolizumab therapy. Two months after she was discharged from the hospital, she continued to take insulin as well as metformin to treat her diabetes. Clinicians need to be alert about diabetes mellitus and ketoacidosis for patients undergoing pembrolizumab treatment.Keywords: DKA, diabetic ketoacidosis, pembrolizumab, metastatic melanoma
format	article
author	Wu L Li B
author_facet	Wu L Li B
author_sort	Wu L
title	A Case of Severe Diabetic Ketoacidosis Associated with Pembrolizumab Therapy in a Patient with Metastatic Melanoma
title_short	A Case of Severe Diabetic Ketoacidosis Associated with Pembrolizumab Therapy in a Patient with Metastatic Melanoma
title_full	A Case of Severe Diabetic Ketoacidosis Associated with Pembrolizumab Therapy in a Patient with Metastatic Melanoma
title_fullStr	A Case of Severe Diabetic Ketoacidosis Associated with Pembrolizumab Therapy in a Patient with Metastatic Melanoma
title_full_unstemmed	A Case of Severe Diabetic Ketoacidosis Associated with Pembrolizumab Therapy in a Patient with Metastatic Melanoma
title_sort	case of severe diabetic ketoacidosis associated with pembrolizumab therapy in a patient with metastatic melanoma
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/33fe7cab09894b2498cdbdf58308cf28
work_keys_str_mv	AT wul acaseofseverediabeticketoacidosisassociatedwithpembrolizumabtherapyinapatientwithmetastaticmelanoma AT lib acaseofseverediabeticketoacidosisassociatedwithpembrolizumabtherapyinapatientwithmetastaticmelanoma AT wul caseofseverediabeticketoacidosisassociatedwithpembrolizumabtherapyinapatientwithmetastaticmelanoma AT lib caseofseverediabeticketoacidosisassociatedwithpembrolizumabtherapyinapatientwithmetastaticmelanoma
_version_	1718392072330805248

A Case of Severe Diabetic Ketoacidosis Associated with Pembrolizumab Therapy in a Patient with Metastatic Melanoma

Ejemplares similares